US14070B3096 - Common Stock
CAPRICOR THERAPEUTICS INC
NASDAQ:CAPR (5/3/2024, 4:20:01 PM)
5.47
+0.23 (+4.39%)
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. The company is headquartered in Beverly Hills, California and currently employs 74 full-time employees. The company went IPO on 2002-06-04. The firm is focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. The Company’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is in late-stage clinical development for treating Duchenne muscular dystrophy (DMD). CAP-1002 is designed to slow disease progression in DMD through the immunomodulatory, anti-inflammatory, and anti-fibrotic actions of cardiosphere-derived cells (CDCs), which are mediated by secreted exosomes laden with bioactive cargo. CAP-2003 is the name of its exosomes product candidate, which is derived from its CDCs. The company is also developing its exosome technology as a therapeutic platform. The Company’s focus is on developing exosomes capable of delivering nucleic acids, including messenger RNA (mRNA), as well as proteins to treat or prevent a variety of diseases.
CAPRICOR THERAPEUTICS INC
8840 Wilshire Blvd, 2nd Floor
Beverly Hills CALIFORNIA 90211
P: 13103583200
CEO: Linda Marban
Employees: 74
Website: https://capricor.com/
-Company Aligned with FDA on Demonstration of Non-Clinical Comparability; Allowing for Immediate Use of San Diego Manufacturing Facility-
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and...
Presentation Highlights Positive 24-Month Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy...
-Enrollment Complete in Cohort A of Phase 3, Pivotal, HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy; Announced Successful Interim Futility...
Major earnings expected after the bell on Thursday include:Zscaler (ZS)Hewlett Packard Enterprise Company (HPE)Dell Technologies (DELL)Autodesk (ADSK)Veeva...
SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- – Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and...
Here you can normally see the latest stock twits on CAPR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: